NR 566 Advanced Pharmacology Final Exam Test
Bank | Complete 150 Q&A Bundle with Verified
Answers & Rationales (Chamberlain / Across
Lifespan)
Question 1
Question: A 65-year-old male with chronic heart failure with reduced ejection fraction
(HFrEF, EF 32%) and stage 3 chronic kidney disease (eGFR 41 mL/min) presents for
routine optimization. His current regimen includes Carvedilol and Losartan. His vitals
are stable, but his potassium level is 4.4 mEq/L. According to gold-standard guidelines,
which modification provides the highest mortality reduction?
A) Discontinue Losartan and initiate Hydralazine plus Isosorbide Dinitrate.
B) Add Spironolactone 12.5 mg daily with close monitoring of potassium and renal
function.
C) Discontinue Losartan, enforce a 36-hour washout window, and initiate
Sacubitril/Valsartan.
D) Add Digoxin 0.125 mg daily to improve myocardial contractility.
Correct Answer: C) Discontinue Losartan, enforce a 36-hour washout window,
and initiate Sacubitril/Valsartan.
Detailed Rationale: Guideline-Directed Medical Therapy (GDMT) strongly mandates
replacing an ACE inhibitor or ARB with an Angiotensin Receptor-Neprilysin Inhibitor
(ARNI) like Sacubitril/Valsartan for patients with HFrEF to significantly reduce
cardiovascular mortality and hospitalizations. A strict 36-hour washout period is required
when switching from an ACE inhibitor to prevent life-threatening angioedema. While
, switching from an ARB (like Losartan) does not technically carry the same biochemical
bradykinin-accumulation risk as an ACE inhibitor, clinical standards and board-style
exams enforce uniform adherence to safety washout timelines or emphasize the
superiority of ARNIs over basic ARBs. Spironolactone (Option B) also reduces mortality
but replacing the baseline ARB with an ARNI takes clinical precedence as a primary
foundational step. Digoxin (Option D) does not reduce mortality; it only reduces
hospitalizations.
Question 2
Question: A 45-year-old female is initiated on Warfarin for a mechanical mitral valve
replacement. On day 3 of therapy, she develops painful, sharply demarcated purpuric
lesions across her thighs and abdomen that rapidly progress to necrotic eschars. What
is the underlying pathophysiological mechanism of this severe drug reaction?
A) Immune-mediated destruction of platelets via Heparin-Induced Thrombocytopenia
(HIT) antibodies.
B) Immediate Type I hypersensitivity reaction causing localized cutaneous anaphylaxis.
C) Rapid depletion of endogenous Protein C and Protein S prior to the clearance of
clotting factors II, IX, and X.
D) Structural damage to endothelial cells caused by an accumulation of toxic
metabolites of vitamin K.
Correct Answer: C) Rapid depletion of endogenous Protein C and Protein S prior
to the clearance of clotting factors II, IX, and X.
Detailed Rationale: Warfarin inhibits Vitamin K Epoxide Reductase (VKORC1),
blocking the synthesis of functional clotting factors II, VII, IX, and X, as well as the
endogenous anticoagulant proteins C and S. Protein C has a very short half-life (~6 to 8
hours) compared to procoagulant factors like factor II (prothrombin, ~60 hours). During
the first few days of Warfarin initiation, natural anticoagulants drop rapidly while
procoagulant levels remain high, creating a transient hypercoagulable state. In patients
with underlying deficiencies or high initial loading doses, this leads to microvascular
thrombosis, skin necrosis, and gangrene.
Question 3
Question: An APRN evaluates a 68-year-old African American female with newly
diagnosed Stage 2 Hypertension (BP 152/94 mmHg). She has no history of diabetes,
chronic kidney disease, or cardiovascular events. According to JNC-8 and ACC/AHA
guidelines, which initial pharmacotherapy regimen is most appropriate?
A) Lisinopril 10 mg daily monotherapy.
B) Metoprolol Succinate 25 mg daily monotherapy.
C) A combination of Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg daily.
D) Losartan 50 mg daily monotherapy.
Correct Answer: C) A combination of Amlodipine 5 mg and Hydrochlorothiazide
12.5 mg daily.
Detailed Rationale: For African American patients without chronic kidney disease,
clinical guidelines state that initial antihypertensive therapy should include a thiazide-
type diuretic or a Calcium Channel Blocker (CCB), either as monotherapy or in
, combination. Because her blood pressure is in the Stage 2 range and more than 20/10
mmHg above her target (<130/80 mmHg), initiating therapy with two first-line agents
from different classes increases the probability of achieving timely blood pressure
control. Renin-angiotensin system blockers (Options A and D) are less effective as
monotherapy in black populations due to a higher prevalence of low-renin hypertension.
Beta-blockers (Option B) are no longer recommended as first-line agents for primary
hypertension without compelling indications (e.g., post-MI, heart failure).
Question 4
Question: A patient taking Amiodarone 200 mg daily for the management of refractory
atrial fibrillation presents for a comprehensive wellness visit. Which diagnostic
monitoring matrix must the APRN routinely order to detect long-term systemic toxicities
associated with this medication?
A) Serum amylase, lipase, and serial abdominal ultrasounds.
B) Thyroid Function Tests (TSH/Free T4), Liver Function Tests (AST/ALT), and a
screening Pulmonary Function Test (PFT) with chest X-ray.
C) Complete Blood Count (CBC) with differential, serum uric acid, and an
echocardiogram.
D) Serial 24-hour urine collections for creatinine clearance and spot protein-to-
creatinine ratios.
Correct Answer: B) Thyroid Function Tests (TSH/Free T4), Liver Function Tests
(AST/ALT), and a screening Pulmonary Function Test (PFT) with chest X-ray.
Detailed Rationale: Amiodarone is a highly iodine-rich lipophilic medication that
accumulates extensively in peripheral tissues, leading to serious organ toxicities. It can
induce both hyperthyroidism and hypothyroidism due to its high iodine structural content
and direct effect on thyroid tissue. It also carries a Black Box Warning for pulmonary
toxicity (interstitial pneumonitis/fibrosis), which can be insidious and fatal. Hepatotoxicity
is another documented adverse effect. Routine surveillance of thyroid, hepatic, and
pulmonary baselines is mandatory for safe chronic preservation.
Question 5
Question: A 72-year-old male with chronic non-valvular atrial fibrillation and a
CHA₂DS₂-VASc score of 4 is initiated on Apixaban (Eliquis). He weighs 58 kg and his
serum creatinine is 1.6 mg/dL. What is the correct dosage adjustment rationale for this
patient?
A) Administer the standard dose of 5 mg orally twice daily because he only meets one
adjustment criterion.
B) Reduce the dose to 2.5 mg orally twice daily because he meets at least two dose-
reduction criteria (Age ≥ 80, Weight ≤ 60 kg, or Creatinine ≥ 1.5 mg/dL).
C) Discontinue Apixaban and switch to low-dose Aspirin because his renal function is
too low.
D) Transition the patient to Warfarin because Direct Oral Anticoagulants (DOACs) are
contraindicated in patients weighing under 60 kg.
Correct Answer: A) Administer the standard dose of 5 mg orally twice daily
because he only meets one adjustment criterion.
, Detailed Rationale: Apixaban dosing for non-valvular atrial fibrillation requires a
reduction from 5 mg BID to 2.5 mg BID only if the patient meets at least two of the
following characteristics: Age ≥ 80 years, Body weight ≤ 60 kg, or Serum creatinine ≥
1.5 mg/dL. This patient is 72 years old (does not meet age criterion), weighs 58 kg
(meets weight criterion), and has a creatinine of 1.6 mg/dL (meets creatinine criterion).
Because he meets exactly one criterion, reducing the dose would under-anticoagulate
him and significantly increase his risk of an ischemic stroke.
Question 6
Question: A 50-year-old patient with an LDL-cholesterol level of 165 mg/dL and a
calculated 10-year ASCVD risk score of 12.5% is initiated on Atorvastatin 40 mg daily.
Two weeks later, the patient returns complaining of bilateral, symmetrical proximal
muscle aching and weakness without trauma. What is the most critical initial diagnostic
laboratory evaluation the APRN should order?
A) Serum Rheumatoid Factor (RF) and Antinuclear Antibody (ANA).
B) Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP).
C) Serum Creatine Kinase (CK) level.
D) Complete metabolic panel to evaluate total serum albumin levels.
Correct Answer: C) Serum Creatine Kinase (CK) level.
Detailed Rationale: Statin-induced myopathy ranges from mild myalgia to life-
threatening rhabdomyolysis. When a patient presents with new-onset, unexplained
bilateral muscle pain or weakness while on statin therapy, the priority is to measure a
serum Creatine Kinase (CK) level to rule out structural muscle damage. If the CK level
is profoundly elevated (typically >10 times the upper limit of normal) and accompanied
by renal impairment, the statin must be discontinued immediately to prevent acute
kidney injury from myoglobinuria.
Question 7
Question: An APRN is reviewing the laboratory results of a patient receiving chronic
Loop Diuretic therapy (Furosemide 40 mg BID) for volume management in severe heart
failure. Which metabolic and electrolyte derangement constellation is most
characteristically produced by high-dose loop diuretic usage?
A) Hypokalemia, Hyponatremia, Hypomagnesemia, and Metabolic Alkalosis.
B) Hyperkalemia, Hypercalcemia, Hyponatremia, and Metabolic Acidosis.
C) Hypokalemia, Hypotoxicemia, Hypernatremia, and Respiratory Acidosis.
D) Hyperkalemia, Hypocalcemia, Hypermagnesemia, and Non-gap Metabolic Acidosis.
Correct Answer: A) Hypokalemia, Hyponatremia, Hypomagnesemia, and
Metabolic Alkalosis.
Detailed Rationale: Loop diuretics inhibit the Na⁺/K⁺/2Cl⁻ cotransporter in the thick
ascending limb of the loop of Henle. By blocking this channel, they cause massive
urinary excretion of sodium, potassium, chloride, calcium, and magnesium. The delivery
of excess sodium to the distal nephron accelerates potassium and hydrogen ion
secretion into the urine, which characteristically results in hypokalemic, hypochloremic
metabolic alkalosis alongside structural hyponatremia and hypomagnesemia.
Question 8
Bank | Complete 150 Q&A Bundle with Verified
Answers & Rationales (Chamberlain / Across
Lifespan)
Question 1
Question: A 65-year-old male with chronic heart failure with reduced ejection fraction
(HFrEF, EF 32%) and stage 3 chronic kidney disease (eGFR 41 mL/min) presents for
routine optimization. His current regimen includes Carvedilol and Losartan. His vitals
are stable, but his potassium level is 4.4 mEq/L. According to gold-standard guidelines,
which modification provides the highest mortality reduction?
A) Discontinue Losartan and initiate Hydralazine plus Isosorbide Dinitrate.
B) Add Spironolactone 12.5 mg daily with close monitoring of potassium and renal
function.
C) Discontinue Losartan, enforce a 36-hour washout window, and initiate
Sacubitril/Valsartan.
D) Add Digoxin 0.125 mg daily to improve myocardial contractility.
Correct Answer: C) Discontinue Losartan, enforce a 36-hour washout window,
and initiate Sacubitril/Valsartan.
Detailed Rationale: Guideline-Directed Medical Therapy (GDMT) strongly mandates
replacing an ACE inhibitor or ARB with an Angiotensin Receptor-Neprilysin Inhibitor
(ARNI) like Sacubitril/Valsartan for patients with HFrEF to significantly reduce
cardiovascular mortality and hospitalizations. A strict 36-hour washout period is required
when switching from an ACE inhibitor to prevent life-threatening angioedema. While
, switching from an ARB (like Losartan) does not technically carry the same biochemical
bradykinin-accumulation risk as an ACE inhibitor, clinical standards and board-style
exams enforce uniform adherence to safety washout timelines or emphasize the
superiority of ARNIs over basic ARBs. Spironolactone (Option B) also reduces mortality
but replacing the baseline ARB with an ARNI takes clinical precedence as a primary
foundational step. Digoxin (Option D) does not reduce mortality; it only reduces
hospitalizations.
Question 2
Question: A 45-year-old female is initiated on Warfarin for a mechanical mitral valve
replacement. On day 3 of therapy, she develops painful, sharply demarcated purpuric
lesions across her thighs and abdomen that rapidly progress to necrotic eschars. What
is the underlying pathophysiological mechanism of this severe drug reaction?
A) Immune-mediated destruction of platelets via Heparin-Induced Thrombocytopenia
(HIT) antibodies.
B) Immediate Type I hypersensitivity reaction causing localized cutaneous anaphylaxis.
C) Rapid depletion of endogenous Protein C and Protein S prior to the clearance of
clotting factors II, IX, and X.
D) Structural damage to endothelial cells caused by an accumulation of toxic
metabolites of vitamin K.
Correct Answer: C) Rapid depletion of endogenous Protein C and Protein S prior
to the clearance of clotting factors II, IX, and X.
Detailed Rationale: Warfarin inhibits Vitamin K Epoxide Reductase (VKORC1),
blocking the synthesis of functional clotting factors II, VII, IX, and X, as well as the
endogenous anticoagulant proteins C and S. Protein C has a very short half-life (~6 to 8
hours) compared to procoagulant factors like factor II (prothrombin, ~60 hours). During
the first few days of Warfarin initiation, natural anticoagulants drop rapidly while
procoagulant levels remain high, creating a transient hypercoagulable state. In patients
with underlying deficiencies or high initial loading doses, this leads to microvascular
thrombosis, skin necrosis, and gangrene.
Question 3
Question: An APRN evaluates a 68-year-old African American female with newly
diagnosed Stage 2 Hypertension (BP 152/94 mmHg). She has no history of diabetes,
chronic kidney disease, or cardiovascular events. According to JNC-8 and ACC/AHA
guidelines, which initial pharmacotherapy regimen is most appropriate?
A) Lisinopril 10 mg daily monotherapy.
B) Metoprolol Succinate 25 mg daily monotherapy.
C) A combination of Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg daily.
D) Losartan 50 mg daily monotherapy.
Correct Answer: C) A combination of Amlodipine 5 mg and Hydrochlorothiazide
12.5 mg daily.
Detailed Rationale: For African American patients without chronic kidney disease,
clinical guidelines state that initial antihypertensive therapy should include a thiazide-
type diuretic or a Calcium Channel Blocker (CCB), either as monotherapy or in
, combination. Because her blood pressure is in the Stage 2 range and more than 20/10
mmHg above her target (<130/80 mmHg), initiating therapy with two first-line agents
from different classes increases the probability of achieving timely blood pressure
control. Renin-angiotensin system blockers (Options A and D) are less effective as
monotherapy in black populations due to a higher prevalence of low-renin hypertension.
Beta-blockers (Option B) are no longer recommended as first-line agents for primary
hypertension without compelling indications (e.g., post-MI, heart failure).
Question 4
Question: A patient taking Amiodarone 200 mg daily for the management of refractory
atrial fibrillation presents for a comprehensive wellness visit. Which diagnostic
monitoring matrix must the APRN routinely order to detect long-term systemic toxicities
associated with this medication?
A) Serum amylase, lipase, and serial abdominal ultrasounds.
B) Thyroid Function Tests (TSH/Free T4), Liver Function Tests (AST/ALT), and a
screening Pulmonary Function Test (PFT) with chest X-ray.
C) Complete Blood Count (CBC) with differential, serum uric acid, and an
echocardiogram.
D) Serial 24-hour urine collections for creatinine clearance and spot protein-to-
creatinine ratios.
Correct Answer: B) Thyroid Function Tests (TSH/Free T4), Liver Function Tests
(AST/ALT), and a screening Pulmonary Function Test (PFT) with chest X-ray.
Detailed Rationale: Amiodarone is a highly iodine-rich lipophilic medication that
accumulates extensively in peripheral tissues, leading to serious organ toxicities. It can
induce both hyperthyroidism and hypothyroidism due to its high iodine structural content
and direct effect on thyroid tissue. It also carries a Black Box Warning for pulmonary
toxicity (interstitial pneumonitis/fibrosis), which can be insidious and fatal. Hepatotoxicity
is another documented adverse effect. Routine surveillance of thyroid, hepatic, and
pulmonary baselines is mandatory for safe chronic preservation.
Question 5
Question: A 72-year-old male with chronic non-valvular atrial fibrillation and a
CHA₂DS₂-VASc score of 4 is initiated on Apixaban (Eliquis). He weighs 58 kg and his
serum creatinine is 1.6 mg/dL. What is the correct dosage adjustment rationale for this
patient?
A) Administer the standard dose of 5 mg orally twice daily because he only meets one
adjustment criterion.
B) Reduce the dose to 2.5 mg orally twice daily because he meets at least two dose-
reduction criteria (Age ≥ 80, Weight ≤ 60 kg, or Creatinine ≥ 1.5 mg/dL).
C) Discontinue Apixaban and switch to low-dose Aspirin because his renal function is
too low.
D) Transition the patient to Warfarin because Direct Oral Anticoagulants (DOACs) are
contraindicated in patients weighing under 60 kg.
Correct Answer: A) Administer the standard dose of 5 mg orally twice daily
because he only meets one adjustment criterion.
, Detailed Rationale: Apixaban dosing for non-valvular atrial fibrillation requires a
reduction from 5 mg BID to 2.5 mg BID only if the patient meets at least two of the
following characteristics: Age ≥ 80 years, Body weight ≤ 60 kg, or Serum creatinine ≥
1.5 mg/dL. This patient is 72 years old (does not meet age criterion), weighs 58 kg
(meets weight criterion), and has a creatinine of 1.6 mg/dL (meets creatinine criterion).
Because he meets exactly one criterion, reducing the dose would under-anticoagulate
him and significantly increase his risk of an ischemic stroke.
Question 6
Question: A 50-year-old patient with an LDL-cholesterol level of 165 mg/dL and a
calculated 10-year ASCVD risk score of 12.5% is initiated on Atorvastatin 40 mg daily.
Two weeks later, the patient returns complaining of bilateral, symmetrical proximal
muscle aching and weakness without trauma. What is the most critical initial diagnostic
laboratory evaluation the APRN should order?
A) Serum Rheumatoid Factor (RF) and Antinuclear Antibody (ANA).
B) Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP).
C) Serum Creatine Kinase (CK) level.
D) Complete metabolic panel to evaluate total serum albumin levels.
Correct Answer: C) Serum Creatine Kinase (CK) level.
Detailed Rationale: Statin-induced myopathy ranges from mild myalgia to life-
threatening rhabdomyolysis. When a patient presents with new-onset, unexplained
bilateral muscle pain or weakness while on statin therapy, the priority is to measure a
serum Creatine Kinase (CK) level to rule out structural muscle damage. If the CK level
is profoundly elevated (typically >10 times the upper limit of normal) and accompanied
by renal impairment, the statin must be discontinued immediately to prevent acute
kidney injury from myoglobinuria.
Question 7
Question: An APRN is reviewing the laboratory results of a patient receiving chronic
Loop Diuretic therapy (Furosemide 40 mg BID) for volume management in severe heart
failure. Which metabolic and electrolyte derangement constellation is most
characteristically produced by high-dose loop diuretic usage?
A) Hypokalemia, Hyponatremia, Hypomagnesemia, and Metabolic Alkalosis.
B) Hyperkalemia, Hypercalcemia, Hyponatremia, and Metabolic Acidosis.
C) Hypokalemia, Hypotoxicemia, Hypernatremia, and Respiratory Acidosis.
D) Hyperkalemia, Hypocalcemia, Hypermagnesemia, and Non-gap Metabolic Acidosis.
Correct Answer: A) Hypokalemia, Hyponatremia, Hypomagnesemia, and
Metabolic Alkalosis.
Detailed Rationale: Loop diuretics inhibit the Na⁺/K⁺/2Cl⁻ cotransporter in the thick
ascending limb of the loop of Henle. By blocking this channel, they cause massive
urinary excretion of sodium, potassium, chloride, calcium, and magnesium. The delivery
of excess sodium to the distal nephron accelerates potassium and hydrogen ion
secretion into the urine, which characteristically results in hypokalemic, hypochloremic
metabolic alkalosis alongside structural hyponatremia and hypomagnesemia.
Question 8
